Financial Impact - Ctrip (TCOM) is under investigation for alleged monopolistic practices, with a potential fine estimated at RMB 1.5 billion, representing 4% of its 2024 domestic revenue[2][5] - The financial impact of the fine is considered limited, with a projected net profit margin decrease of 2 percentage points for the 2026 fiscal year[5][10] Revenue Projections - Ctrip's total revenue for the 2026 fiscal year is expected to reach RMB 70.1 billion, reflecting a 13% year-on-year growth[10][11] - Domestic accommodation revenue is projected to grow by 3% year-on-year, while overall accommodation revenue is expected to increase by 13%[10][11] Profitability Metrics - Non-GAAP operating profit for 2026 is estimated at RMB 19.1 billion, a 5% increase from the previous year, with a profit margin of 27%, down 2 percentage points[10][11] - The net commission rate is expected to stabilize at 8.8%, which is within the historical range of 8%-10%[10][11] Market Position and Risks - Ctrip is expected to maintain its leading position in the online travel market, but faces risks of market share loss due to regulatory pressures and competition[8][9] - Potential loss of price-sensitive customers and hotel inventory could occur if Ctrip allows merchants to set their own prices without inventory lock-in[9] Valuation Outlook - Ctrip's valuation may revert to historical levels of 12-15 times earnings, with the stock price potentially dropping to a range of USD 44-55 per ADR[15] - The company’s valuation has been driven by strong revenue growth and profit margin expansion, but regulatory scrutiny may hinder future profitability[15]

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 6.83 HKD, reflecting a 9% downside based on a 2025 PE of 10X [8][11]. Core Insights - The company focuses on mass professional sports, leading industry turnover growth, and is committed to technological innovation and product upgrades, with rapid expansion of super stores [8][10]. - The company achieved steady turnover growth in Q4 2025, with main brand offline, online, and children's turnover growing by 10%, high double digits, and 10% year-on-year respectively [9][10]. - The company exceeded its annual opening target for super stores, with 126 stores opened by the end of 2025, surpassing the initial target of 100 stores [10][11]. - The company is increasing its focus on mental products and professional events, with successful product launches and event sponsorships planned for 2026 [11]. Financial Summary - Projected total revenue for 2024A, 2025E, 2026E, and 2027E is 10,074 million, 11,147 million, 12,355 million, and 13,732 million RMB respectively, reflecting growth rates of 19.6%, 10.7%, 10.8%, and 11.1% [3]. - Projected net profit attributable to shareholders for 2025-2027 is 1,271 million, 1,403 million, and 1,560 million RMB, with corresponding PE ratios of 8.5X, 7.7X, and 6.9X [3][8]. - The company’s gross profit is expected to increase from 4,183 million RMB in 2024A to 5,633 million RMB in 2027E, maintaining a gross margin around 40% [3].

Acquisitions - Charles River announced the strategic acquisition of K.F. (Cambodia) Ltd. for approximately $510 million, expected to complete in Q1 2026, to self-supply most annual NHP needs[4] - The company will also acquire the remaining 79% of PathoQuest for about €51.60 million (approximately $60 million), expected to contribute $15-20 million in revenue in 2026[4] Supply Chain and Technology Enhancement - The acquisition of K.F. will aid in vertical integration amid global NHP resource constraints, enhancing DSA business stability and cost control[5] - PathoQuest's NGS quality control technology will improve NAMs and bioproduct quality control, increasing the proportion of high-value services[5] DSA Demand Recovery - DSA net book-to-bill ratio reached 1.1x in Q4 2025, up from 0.8x in Q2-Q3 2025, indicating a recovery driven by small and medium biotech demand and growth in large pharma orders[6] - This recovery signals a gradual bottoming out of preclinical demand[6] 2026 Performance Outlook - The company is cautiously optimistic for 2026, expecting organic revenue growth to be at least flat, with DSA business resuming organic growth in H2 2026[6] - Forex is expected to contribute 100-150 basis points to revenue growth[6] Investment Recommendations - Long-term positive outlook on pharmaceutical growth, with a focus on domestic companies such as WuXi AppTec and Pharmaron[7] - Suggested companies to watch include WuXi AppTec, Pharmaron, JOINN Laboratories, and others[7] Risk Factors - Risks include a weaker-than-expected global biotech financing environment and challenges in NHP supply chain recovery[7] - Potential risks related to acquisition integration and project execution[7]

Investment Rating - The report initiates coverage with an OUTPERFORM rating, setting a target price of RMB 206.00 based on a current price of RMB 165.46 [2]. Core Insights - The company, Sungrow Power Supply, is positioned as a leader in the global photovoltaic inverter market and is experiencing significant growth in its energy storage business, which is expected to become the primary growth engine [3][5]. - The global photovoltaic installation demand is projected to continue its long-term growth trend, with new installations expected to reach approximately 610GW in 2025 and 642GW in 2026 [4][33]. - The energy storage market is anticipated to see a compound annual growth rate (CAGR) exceeding 50% from 2021 to 2027, with large-scale storage installations expected to rise from 28.4GWh to 605GWh [5][42]. Company Overview - Sungrow Power Supply was established in 1997 and went public in 2011, focusing on the research, production, and sales of renewable energy equipment, including photovoltaic, wind, storage, and hydrogen energy technologies [9][11]. - The company has built a comprehensive industrial chain covering core equipment manufacturing, system integration, and energy services, forming a synergistic ecosystem [9][10]. Photovoltaic Inverters - The company maintains a leading market share in photovoltaic inverters, with a global shipment volume of 147GW in 2024, representing a year-on-year growth of 13.08% and a market share of approximately 23%-25% [4][41]. - The product matrix includes a range of inverters suitable for various applications, from residential to large-scale ground-mounted power plants, ensuring a robust global presence [3][10]. Energy Storage - The energy storage business is expected to surpass the photovoltaic inverter segment as the primary growth driver by 2025, with significant orders and a high proportion of overseas orders [5][42]. - The company has developed advanced energy storage solutions, including the PowerTitan liquid-cooled storage system, which has been successfully implemented in major projects [10][42]. Financial Performance - For the first three quarters of 2025, the company reported revenues of RMB 664.02 billion, a year-on-year increase of 32.95%, and a net profit of RMB 118.81 billion, reflecting a substantial growth of 56.34% [22][23]. - The gross profit margin improved to 34.88%, indicating enhanced profitability and cash flow management [22][23]. Global Expansion - Sungrow Power Supply has expanded its operations to over 180 countries, with a strong presence in Europe, North America, the Middle East, and emerging markets [30][42]. - The company is well-positioned to benefit from the increasing demand for renewable energy solutions globally, particularly in large-scale storage projects [42][46].

Investment Rating - The report indicates a positive outlook for the AI+Pharma and AI+Healthcare sectors, suggesting a shift towards data and algorithm-driven drug development and clinical applications [3][6]. Core Insights - The collaboration between NVIDIA and Eli Lilly to establish the first AI+Pharma joint innovation lab signifies a major step in integrating AI into drug R&D, with a planned investment of up to 1 billion USD over five years [3][6]. - Tempus AI's preliminary revenue for 2025 reached approximately 1.27 billion USD, reflecting an 83% year-over-year growth, validating the commercial viability of AI in clinical testing and medical data [3][6]. - The industry is currently experiencing a phase characterized by technological breakthroughs, active funding, and accelerated application of AI in pharmaceuticals and healthcare [3][6]. Summary by Sections AI+Pharma - The establishment of the AI+Pharma lab aims to address key challenges in drug development, combining expertise from both NVIDIA and Eli Lilly [3][6]. - The partnership is expected to elevate AI's role from a mere tool to a core productivity driver in drug R&D, transitioning the industry from experience-driven to data-driven methodologies [3][6]. AI+Healthcare - Tempus AI reported a diagnostic revenue of approximately 955 million USD, up 111% year-over-year, driven by significant growth in oncology and genetic testing [3][6]. - The data and application segment generated about 316 million USD, marking a 31% increase, with data licensing (Insights) growing by 38% [3][6]. Industry Trends - The report highlights a favorable environment for AI in pharmaceuticals, supported by technological advancements, policy backing, and a vibrant investment landscape [3][6]. - The launch of OpenAI's ChatGPT Health and the significant user engagement indicate a growing interest and application of AI technologies in healthcare [3][6]. - Relevant investment targets in AI drug discovery and healthcare applications include companies like XtalPi, Insilico Medicine, and Meinian Onehealth [3][6].

研究报告 Research Report 15 Jan 2026 李宁 LI NING (2331 HK) 4Q25 营运表现点评：4Q25 流水符合预期，上调 25 年净利率指引 4Q25 Operating Review: GMV in Line with Expectations; 25E Net Profit Margin Guidance Raised [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$19.55 目标价 HK$22.30 HTI ESG 0.8-2.2-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$50.53bn / US$6.48bn 日交易额 (3 个月均值) US$42.39mn 发行股票数目 2,585mn 自由流通股 (%) 86% 1 年股价最高最低值 HK$20.28-HK$13.96 注：现价 HK$19.55 为 20 ...

Investment Rating - The report indicates a strong investment outlook for the data center sector, predicting global investments to reach at least $3 trillion over the next five years, driven by AI and major cloud providers [2]. Core Insights - The report highlights the rapid expansion of data center capacity driven by AI, with major U.S. companies expected to spend nearly $400 billion in 2025, with an additional $200 billion anticipated in the following two years [2][8]. - The report notes that the cost of supplying power to data centers has reached $6.5 billion, accounting for 40% of total auction costs in the latest capacity auction by PJM [2]. - The Texas power reliability council (ERCOT) has seen a surge in large load interconnection requests, increasing by approximately 300% to over 233 GW, with over 70% attributed to data centers [2]. - The report discusses the challenges faced by the energy market, including the freezing of offshore wind power projects, leading to significant daily losses for developers [2]. - MISO plans to invest about $1.2 billion in a new transmission line in Wisconsin as part of a long-term $22 billion transmission plan to strengthen the grid [2]. Summary by Sections Global Infrastructure and Construction Equipment - Moody's forecasts that global data center investments will reach at least $3 trillion over the next five years, primarily driven by AI and major cloud providers [2][8]. - The report emphasizes the evolving financing models in capital markets, with institutional investors increasingly participating in lending during the construction phase [8]. - The report also highlights the rising construction costs due to increased prices for critical inputs like construction equipment and GPUs, which are expected to further elevate the costs of new data centers [8]. Global Electrical and Intelligent Equipment - The gas turbine price index increased by 5.49% year-on-year and 2.1% month-on-month as of September 2025, indicating a stable demand in the market [15]. - The report notes that the U.S. gas turbine market's future growth will be driven by re-industrialization and the development of AI data centers [17]. Global Energy Industry - The average retail electricity price in the U.S. as of October 2025 was 13.63 cents/kWh, reflecting a year-on-year increase of 5% across various sectors [4]. - The report indicates that the U.S. electricity demand growth forecast has been revised upwards, with expectations of a 15.8% increase by 2029 [22]. Global New Materials - The report mentions that the global uranium spot price was $81.55 per pound as of December 2025, reflecting an 8% increase month-on-month and a 12% increase year-on-year [4]. Key Company Insights - The report suggests focusing on AI power operators such as Entergy, Talen Energy, and Constellation Energy, as well as energy equipment companies like Oklo and NuScale Power [5]. - It highlights the need for infrastructure improvements in the U.S. energy grid to support industrial return, AI data center construction, and decarbonization efforts [5]. - The report also points out that the demand for high-voltage transmission lines is expected to grow, with companies like Hitachi and Hyundai Electric being key players in this sector [5].

Employment Market Overview - The unemployment rate in the U.S. fell to 4.4% in December, better than the expected 4.5%[6] - The unemployment rate for November was revised down to 4.5%, interrupting the previous upward trend[6] - The U6 unemployment rate decreased by 0.3 percentage points to 8.4%, indicating reduced pressure on marginally employed groups[10] Job Creation and Market Conditions - Non-farm payrolls added only 50,000 jobs in December, falling short of the market expectation of 65,000[19] - Job additions for October and November were revised down by a total of 76,000, with October's figures adjusted from -105,000 to -173,000[19] - The average weekly hours worked decreased to 34.2 hours, while average hourly earnings increased by 0.3% month-over-month and 3.8% year-over-year, slightly above the expected 3.6%[13] Federal Reserve Outlook - The Federal Reserve has room to pause interest rate cuts in January, with a current market expectation of only a 5% probability for a rate cut[26] - The market anticipates two rate cuts in 2026, now pushed to June and September[26] Risks and Considerations - Political pressure from Trump could further threaten the independence of the Federal Reserve[27]

美国通胀：延续温和 宏 观 快 报 点 评 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 2025 年 12 月美国通胀数据点评 本报告导读： 12 月美国通胀并未出现市场此前所担忧的补偿性反弹，核心 CPI 增速反而不及预期。 结构上来看核心商品通胀温和，核心服务通胀有所回升。短期内美国通胀压力或仍 偏温和，不会对市场情绪以及美联储货币政策决定带来过多扰动。 投资要点： 宏 观 研 究 宏观研究 /[Table_Date] 2026.01.14 2026-01-14 [Table_Summary] 美国 12 月通胀：反弹幅度不及预期。数据公布前，市场普遍认为由 于政府关门导致 11 月通胀数据被低估，12 月通胀数据会出现补偿 性反弹。但 12 月美国 CPI 同比增速维持 2.7%，与 11 月持平；环比 增速维持 0.3%，与 9 月持平，并未出现明显回升。此外，核心 CPI 增速反而低于预期。其中核心 CPI 同比 2.6%（市场预期 2.7%，前值 2.6%），核心 CPI 环比 0.2%（市场预期 0.3%）。总体来看，12 月通胀 数据显示美国当前通胀压力仍较温和。 结构：商品偏弱 ...

Investment Rating - The report initiates coverage with an OUTPERFORM rating for Giant Biogene, with a target price of HK$43.60, indicating a potential upside of 22.0% from the current price of HK$35.74 [1][2][7]. Core Insights - The report expresses a long-term positive outlook on the recombinant collagen sector, highlighting its advantages in safety, efficacy, and sustainability, which are seen as fundamental drivers for industry growth [4][34]. - Giant Biogene has established itself as a leader in the recombinant collagen market, with a strategic shift towards brand development in 2026 [9][30]. Financial Summary - Revenue projections for 2025, 2026, and 2027 are estimated at RMB 54.9 billion, RMB 59.9 billion, and RMB 66.9 billion, respectively, with expected growth rates of -0.9%, 9.1%, and 11.8% [7][32]. - Net profit forecasts for the same years are RMB 18.8 billion, RMB 20.0 billion, and RMB 22.1 billion, with growth rates of -9.0%, 6.6%, and 10.5% [7][32]. - The gross profit margin is expected to remain stable at approximately 80.5% in 2025, declining slightly to 79.2% by 2027 [7][32]. Brand and Product Strategy - Giant Biogene operates eight brands, with the core brands being Kefu Mei and Keli Jin, which contribute over 95% of the company's revenue [5][11][13]. - The company plans to launch a medical device and five skincare series in 2026, alongside a brand revamp for Keli Jin [6][30][31]. - The focus will be on expanding both online and offline channels, with plans to increase the number of physical stores and enhance partnerships with high-potential retailers [31][32]. Market Position and Challenges - The company faces short-term challenges due to discussions around the content and testing methods of recombinant collagen, which have impacted sales, particularly for the Kefu Mei brand [18][20][25]. - Despite these challenges, the company is adjusting its strategies, including enhancing online marketing and product offerings to stabilize and grow its market presence [25][29][30].